Walk into any hospital room and you are likely to find infusion pumps bearing the IMED or IVAC names. Stories of these companies convey themes typical of venture finance technological innovation driving higher valuations leading to a spectacular sale. (use italics in yellow/gold)These five broadly different case studies of major healthcare device companies and a biotechnology start-up to public company provide the reader with a rich cross section of business issues and answers. This book should be of interest to anyone in the health care industry, as well as to the general business reader. The cases provide a venture capitalist's and manager's view of how to start and build a company.The author was lead VC in each of these five companies. There is a detailed description of the issues and problems which occur in developing young companies to create significant value. The way problems and successes were dealt with gives the reader a broad learning experience ranging from the damage of patent infringement to being first in a market with runaway initial acceptance and learning how to keep the lead.Each of these cases comes from Henry Venture Fund investments. The reader learns how the investment opportunity was analyzed, how the investment was priced, how it was managed and directed into its product development and principal markets, and whether success or failure occurred and why. Two of the companies were sold for $400 million each, one was sold for $80 million in 22 months from founding, one declined in value by 90%, or $100 million, and was acquired and taken private and the the biotech company went public.Also included are two new biotech company descriptions which have made significant scientific discoveries. Sinapis Pharma has commenced a human clinical trial for brain trauma and stroke indications. TauTaTis is a preclinical company in Alzheimer's and Parkinson's Disease with very promising scientific data in mouse studies